Dr Andrea Newbold
Honorary (Fellow)
The Sir Peter MacCallum Department of Oncology
42 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Dual Bcl-2/Bcl-xl inhibition via AZD0466 combines with immune checkpoint blockade to enhance anti-tumour activity
DOI: 10.1038/s41419-025-08354-w2025
Journal article
A CDK11-dependent RNA polymerase II pause-checkpoint precedes CDK9-mediated transition to transcriptional elongation
DOI: 10.1016/j.molcel.2025.08.0012023
Conference Proceedings
P1212: RATIONALLY DESIGNED CHIMERIC PI3K-BET BROMODOMAIN INHIBITORS ELICIT CURATIVE RESPONSES IN MYC-DRIVEN LYMPHOMA
DOI: 10.1097/01.hs9.0000971744.43694.692023
Journal article
Rationally designed chimeric PI3K-BET bromodomain inhibitors elicit curative responses in MYC-driven lymphoma
DOI: 10.1073/pnas.23064141202023
Journal article
Stepwise progression of β-selection during T cell development involves histone deacetylation
DOI: 10.26508/lsa.2022016452022
Journal article
The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression
DOI: 10.3389/fonc.2022.8633292021
Journal article
The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer
DOI: 10.1016/j.cell.2021.04.022
RECENT SCHOLARLY WORKS
2021
Journal article
Serine biosynthesis is a metabolic vulnerability in flt3-itd–driven acute myeloid leukemia
DOI: 10.1158/2159-8290.CD-20-07382020
Journal article
AZD4320, a dual inhibitor of bcl-2 and bcl-xl, induces tumor regression in hematologic cancer models without dose-limiting thrombocytopenia
DOI: 10.1158/1078-0432.CCR-20-08632020
Conference Proceedings
REPROGRAMMING OF SERINE METABOLISM IS A METABOLIC VULNERABILITY IN FMS-LIKE TYROSINE KINASE 3 (FLT3) MUTANT ACUTE MYELOID LEUKAEMIA
DOI: 10.1016/j.exphem.2020.09.024